Ionis Pharmaceuticals Inc (IONS) - Net Assets
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has net assets worth $439.02 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.99 Billion) and total liabilities ($2.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IONS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $439.02 Million |
| % of Total Assets | 14.66% |
| Annual Growth Rate | 17.56% |
| 5-Year Change | -36.65% |
| 10-Year Change | 391.23% |
| Growth Volatility | 1598.79 |
Ionis Pharmaceuticals Inc - Net Assets Trend (1990–2025)
This chart illustrates how Ionis Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Ionis Pharmaceuticals Inc worth.
Annual Net Assets for Ionis Pharmaceuticals Inc (1990–2025)
The table below shows the annual net assets of Ionis Pharmaceuticals Inc from 1990 to 2025. Also explore net asset growth rate of Ionis Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $489.09 Million | -16.87% |
| 2024-12-31 | $588.35 Million | +52.15% |
| 2023-12-31 | $386.69 Million | -32.50% |
| 2022-12-31 | $572.89 Million | -25.79% |
| 2021-12-31 | $772.00 Million | -8.42% |
| 2020-12-31 | $843.00 Million | -49.97% |
| 2019-12-31 | $1.69 Billion | +41.94% |
| 2018-12-31 | $1.19 Billion | +183.52% |
| 2017-12-31 | $418.72 Million | +320.55% |
| 2016-12-31 | $99.56 Million | -50.41% |
| 2015-12-31 | $200.79 Million | -22.11% |
| 2014-12-31 | $257.78 Million | -31.87% |
| 2013-12-31 | $378.39 Million | +107.04% |
| 2012-12-31 | $182.77 Million | +6.61% |
| 2011-12-31 | $171.43 Million | -29.90% |
| 2010-12-31 | $244.54 Million | -19.04% |
| 2009-12-31 | $302.06 Million | +189.76% |
| 2008-12-31 | $104.25 Million | +917.75% |
| 2007-12-31 | $10.24 Million | -89.54% |
| 2006-12-31 | $97.90 Million | +3573.62% |
| 2005-12-31 | $2.67 Million | +103.69% |
| 2004-12-31 | $-72.13 Million | -207.38% |
| 2003-12-31 | $67.18 Million | -56.79% |
| 2002-12-31 | $155.48 Million | -30.31% |
| 2001-12-31 | $223.10 Million | +236.16% |
| 2000-12-31 | $66.37 Million | +8195.75% |
| 1999-12-31 | $800.00K | +119.05% |
| 1998-12-31 | $-4.20 Million | -112.03% |
| 1997-12-31 | $34.90 Million | -40.24% |
| 1996-12-31 | $58.40 Million | -23.06% |
| 1995-12-31 | $75.90 Million | +65.00% |
| 1994-12-31 | $46.00 Million | -21.37% |
| 1993-12-31 | $58.50 Million | +46.98% |
| 1992-12-31 | $39.80 Million | -32.66% |
| 1991-12-31 | $59.10 Million | +3376.47% |
| 1990-12-31 | $1.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ionis Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 262399500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $163.00K | 0.03% |
| Other Comprehensive Income | $-25.28 Million | -5.17% |
| Other Components | $3.15 Billion | 643.11% |
| Total Equity | $489.09 Million | 100.00% |
Ionis Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Henry Schein Inc
NASDAQ:HSIC
|
$7.86 Billion |
|
Meridian Energy Ltd
AU:MEZ
|
$7.86 Billion |
|
Riot Platforms, Inc.
NASDAQ:RIOT
|
$7.86 Billion |
|
Wisetech Global Ltd
AU:WTC
|
$7.86 Billion |
|
Suzhou Maxwell Technologies Co Ltd Class A
SHE:300751
|
$7.84 Billion |
|
Glaukos Corp
NYSE:GKOS
|
$7.84 Billion |
|
Ternium SA ADR
NYSE:TX
|
$7.84 Billion |
|
Yes Bank Limited
NSE:YESBANK
|
$7.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ionis Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 588,351,000 to 489,089,000, a change of -99,262,000 (-16.9%).
- Net loss of 381,000,000 reduced equity.
- New share issuances of 192,604,000 increased equity.
- Other comprehensive income increased equity by 5,530,000.
- Other factors increased equity by 83,604,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-381.00 Million | -77.9% |
| Share Issuances | $192.60 Million | +39.38% |
| Other Comprehensive Income | $5.53 Million | +1.13% |
| Other Changes | $83.60 Million | +17.09% |
| Total Change | $- | -16.87% |
Book Value vs Market Value Analysis
This analysis compares Ionis Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 178.68x to 15.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.26 | $47.25 | x |
| 1991-12-31 | $5.71 | $47.25 | x |
| 1992-12-31 | $3.08 | $47.25 | x |
| 1993-12-31 | $3.74 | $47.25 | x |
| 1994-12-31 | $2.35 | $47.25 | x |
| 1995-12-31 | $3.52 | $47.25 | x |
| 1996-12-31 | $2.29 | $47.25 | x |
| 1997-12-31 | $1.31 | $47.25 | x |
| 1998-12-31 | $-0.16 | $47.25 | x |
| 1999-12-31 | $0.03 | $47.25 | x |
| 2000-12-31 | $1.79 | $47.25 | x |
| 2001-12-31 | $5.06 | $47.25 | x |
| 2002-12-31 | $2.85 | $47.25 | x |
| 2003-12-31 | $1.21 | $47.25 | x |
| 2004-12-31 | $-1.27 | $47.25 | x |
| 2005-12-31 | $0.04 | $47.25 | x |
| 2006-12-31 | $0.92 | $47.25 | x |
| 2007-12-31 | $0.01 | $47.25 | x |
| 2008-12-31 | $0.71 | $47.25 | x |
| 2009-12-31 | $2.97 | $47.25 | x |
| 2010-12-31 | $2.47 | $47.25 | x |
| 2011-12-31 | $1.72 | $47.25 | x |
| 2012-12-31 | $1.82 | $47.25 | x |
| 2013-12-31 | $3.42 | $47.25 | x |
| 2014-12-31 | $2.19 | $47.25 | x |
| 2015-12-31 | $1.68 | $47.25 | x |
| 2016-12-31 | $0.82 | $47.25 | x |
| 2017-12-31 | $3.32 | $47.25 | x |
| 2018-12-31 | $8.86 | $47.25 | x |
| 2019-12-31 | $11.79 | $47.25 | x |
| 2020-12-31 | $6.04 | $47.25 | x |
| 2021-12-31 | $5.47 | $47.25 | x |
| 2022-12-31 | $4.04 | $47.25 | x |
| 2023-12-31 | $2.70 | $47.25 | x |
| 2024-12-31 | $3.94 | $47.25 | x |
| 2025-12-31 | $3.06 | $47.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ionis Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -40.36%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 7.20x
- Recent ROE (-77.90%) is above the historical average (-357.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -264.71% | -225.00% | 0.47x | 2.53x | $-4.67 Million |
| 1991 | -14.72% | -138.10% | 0.09x | 1.25x | $-14.61 Million |
| 1992 | -48.99% | -224.14% | 0.16x | 1.39x | $-23.48 Million |
| 1993 | -32.65% | -157.85% | 0.15x | 1.35x | $-24.95 Million |
| 1994 | -39.57% | -180.20% | 0.15x | 1.45x | $-22.80 Million |
| 1995 | -31.23% | -182.31% | 0.13x | 1.31x | $-31.29 Million |
| 1996 | -45.38% | -116.74% | 0.22x | 1.73x | $-32.34 Million |
| 1997 | -89.11% | -95.11% | 0.28x | 3.38x | $-34.59 Million |
| 1998 | 0.00% | -109.69% | 0.41x | 0.00x | $-42.58 Million |
| 1999 | -7400.00% | -174.63% | 0.33x | 128.88x | $-59.28 Million |
| 2000 | -80.59% | -143.56% | 0.20x | 2.76x | $-60.12 Million |
| 2001 | -33.09% | -138.59% | 0.13x | 1.87x | $-96.14 Million |
| 2002 | -46.46% | -90.10% | 0.18x | 2.82x | $-87.79 Million |
| 2003 | -141.41% | -190.03% | 0.15x | 4.99x | $-101.71 Million |
| 2004 | 0.00% | -334.33% | 0.20x | 0.00x | $-135.29 Million |
| 2005 | -2716.74% | -180.40% | 0.24x | 62.43x | $-72.67 Million |
| 2006 | -66.95% | -308.92% | 0.06x | 3.73x | $-52.76 Million |
| 2007 | -1260.78% | -18.84% | 0.23x | 296.86x | $-11.08 Million |
| 2008 | -27.09% | -16.95% | 0.19x | 8.56x | $-24.88 Million |
| 2009 | 53.16% | 127.52% | 0.19x | 2.25x | $125.89 Million |
| 2010 | -25.05% | -56.47% | 0.20x | 2.25x | $-85.71 Million |
| 2011 | -49.47% | -85.58% | 0.20x | 2.83x | $-101.94 Million |
| 2012 | -35.83% | -64.16% | 0.19x | 2.99x | $-83.75 Million |
| 2013 | -16.03% | -41.17% | 0.17x | 2.24x | $-98.48 Million |
| 2014 | -15.12% | -18.20% | 0.22x | 3.71x | $-64.76 Million |
| 2015 | -43.97% | -31.12% | 0.30x | 4.76x | $-108.36 Million |
| 2016 | -86.93% | -24.97% | 0.38x | 9.16x | $-96.51 Million |
| 2017 | 0.08% | 0.07% | 0.39x | 3.16x | $-41.53 Million |
| 2018 | 23.06% | 45.65% | 0.22x | 2.25x | $155.03 Million |
| 2019 | 17.45% | 26.18% | 0.35x | 1.92x | $125.50 Million |
| 2020 | -57.77% | -66.80% | 0.31x | 2.84x | $-571.30 Million |
| 2021 | -3.70% | -3.53% | 0.31x | 3.38x | $-105.80 Million |
| 2022 | -47.08% | -45.92% | 0.23x | 4.42x | $-327.01 Million |
| 2023 | -94.72% | -46.50% | 0.26x | 7.73x | $-404.95 Million |
| 2024 | -77.15% | -64.37% | 0.23x | 5.11x | $-512.73 Million |
| 2025 | -77.90% | -40.36% | 0.27x | 7.20x | $-429.91 Million |
Industry Comparison
This section compares Ionis Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ionis Pharmaceuticals Inc (IONS) | $439.02 Million | -264.71% | 5.82x | $7.85 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more